Recent Updates
Recently added Catalysts
ECOR Positive Sentiment Score: 75/100

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Key Takeaway: electroCore, Inc. has announced the appointment of Thomas Freeburg as VP, Corporate Controller, effective November 11, 2024. As part of his employment commencement, Freeburg has been granted 5,000 restricted stock units under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on his continued employment. This move is aimed at strengthening the company's leadership as it focuses on the commercialization of bioelectronic medicine technologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Thomas Freeburg as VP, Corporate Controller is a key leadership move.
  • The grant of 5,000 RSUs reflects the company's commitment to attracting talent.
  • The structured vesting schedule of RSUs aligns Mr. Freeburg's interests with long-term company performance.

Full Press Release Details

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 5,000 restricted stock units (“RSUs”) to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg’s continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The company’s is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
ECOR Investor Relations

Tags

Frequently Asked Questions

Who is the new VP, Corporate Controller at electroCore?

Thomas Freeburg will be the new VP, Corporate Controller starting November 11, 2024.

What incentive was given to Thomas Freeburg?

He was granted 5,000 RSUs as an inducement for starting his employment.

When do the RSUs granted to Freeburg vest?

The RSUs will vest in three equal parts on the first three anniversaries of the grant.

What is electroCore's focus in the healthcare field?

The company specializes in bioelectronic medicine and non-invasive vagus nerve stimulation.

How does electroCore promote wellness?

They utilize nVNS technology for health management and consumer wellness products.

Last updated: Nov 8, 2024